Shown effect and durable response
Switching to Doptelet showed effect for durable response1
Patients who do not have an adequate response to their TPO-RA treatment may benefit from switching to a different TPO-RA, as recommended by ICR guidelines.2
In a retrospective, observational study, Doptelet produced an effective and durable response, regardless of prior TPO-RA experience.*†1
Switching to Doptelet reduced the need
for concomitant steroids1
In a retrospective, observational study, 23% of patients were receiving concomitant
corticosteroids before switching to Doptelet.1
*23% of patients switched from eltrombopag and 75% of patients switched from romiplostim. One patient had previous treatment experience with both eltrombopag and romiplostim.1
†Total study population included patients with primary or secondary ITP.1
Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo aninvasive procedure. 3
Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). 3
ICR, international consensus report; ITP, immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist.
References
1. Al-Samkari H, Jiang D, Gernsheimer T, et al. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. Br J Haematol. 2022;197(3):359-366. 2. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817. 3. Doptelet Summary of Product Characteristics. 22/05/2025